Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Status:
Not yet recruiting
Trial end date:
2023-09-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability of
administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to
enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks.
Patients will be asked to complete questionnaires, bone marrow biopsies, research lab
collection, and standard of care lab draw. This research will be taking place only at The
Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.